Evidence map›Paper›PMID 39337651›Full record

ReviewInternational journal of molecular sciences2024

Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects.

Yaping Liu, Yingying Huang, Guantao He, Chun Guo, Jinhua Dong, Linping Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Endogenous targeting lipid nanoparticles for systemic mRNA delivery to lung cancer tumors.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  11. Review
  12. Review
  13. RNA-Based Therapies for Inherited Metabolic Disorders.Journal of inherited metabolic disease · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yaping LiuCollege of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yingying HuangCollege of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Guantao HeCenter for Chemical Biology and Drug Discovery, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.ORCID 0000-0002-3347-6588
Chun GuoCollege of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jinhua DongCollege of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Linping WuCenter for Chemical Biology and Drug Discovery, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.ORCID 0000-0001-7579-2987

Funding

Guangdong Pearl River Talents Program No. 2017GC010411National Key R&D Program of China No. 2023YFF0724200Science and Technology Projects in Guangzhou No. 2024A04J3912the Scientific Research Project of the Sixth Affiliated Hospital of Sun Yat-Sen University No. 2022JBGS07
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) have emerged as leading non-viral carriers for messenger RNA (mRNA) delivery in clinical applications. Overcoming challenges in safe and effective mRNA delivery to target tissues and cells, along with controlling release from the delivery vehicle, remains pivotal in mRNA-based therapies. This review elucidates the structure of LNPs, the mechanism for mRNA delivery, and the targeted delivery of LNPs to various cells and tissues, including leukocytes, T-cells, dendritic cells, Kupffer cells, hepatic endothelial cells, and hepatic and extrahepatic tissues. Here, we discuss the applications of mRNA-LNP vaccines for the prevention of infectious diseases and for the treatment of cancer and various genetic diseases. Although challenges remain in terms of delivery efficiency, specific tissue targeting, toxicity, and storage stability, mRNA-LNP technology holds extensive potential for the treatment of diseases.

Indexed as

LipidsNanoparticlesRNA, MessengerAnimalsHumansLiposomesNeoplasmsLipid NanoparticlesLipidsLiposomesRNA, Messengercancergenetic diseasesinfectious diseaselipid nanoparticlesmRNA vaccine

Identifiers

PMID39337651
PMCPMC11432440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.